Type I borosilicate glass vials

German pharmaceutical glass specialist (FRA: 1SXP; IPO September 2023 at ~€3.6B market cap); subsidiary of SCHOTT AG, which is wholly owned by the Carl Zeiss Foundation — a non-profit foundation structure that has owned SCHOTT since 1884. SCHOTT Pharma is the world's largest manufacturer of pharmaceutical primary packaging glass, holding an estimated 35-45% of the global pharmaceutical borosilicate glass tubing market from which vials, ampoules, and syringes are drawn. Type I borosilicate glass has been SCHOTT's core product since founder Otto Schott invented borosilicate glass composition in 1884, and SCHOTT has the longest continuous manufacturing history of any pharmaceutical glass maker. Key pharmaceutical glass vial production plants in Müllheim (Germany), Jena (Germany), Schweinfurt (Germany), and multiple international sites. Supplied hundreds of millions of vials for COVID-19 vaccine programs including BioNTech/Pfizer mRNA vaccines.

Italian pharmaceutical glass packaging company (NYSE: STVN since June 2021 IPO; family-owned by Stevanato family; ~€800M revenue 2023); headquartered in Piombino Dese, Veneto, Italy. Stevanato is the world's second-largest pharmaceutical glass primary packaging manufacturer and the largest independent vial converter — buying borosilicate glass tubing from SCHOTT and converting it to finished pharmaceutical vials, syringes, and cartridges. Also manufactures the vial-forming machines used in vial conversion (through subsidiary Spami). Stevanato's Piombino Dese campus is one of the highest-capacity pharmaceutical glass vial conversion sites in Europe. Major supplier to COVID-19 vaccine programs. Expanding Fishers, Indiana (US) greenfield glass/plastic hybrid plant (opening 2025) for North American market.

German pharmaceutical packaging company (XETRA: GXI; MDAX; ~€1.8B revenue 2023); headquartered in Düsseldorf. Gerresheimer is a major pharmaceutical glass and plastic primary packaging manufacturer serving both Type I glass vials (for injectables) and plastic pharmaceutical containers. Glass manufacturing plants include Wackersdorf (Bavaria) and Tettau (Thuringia) in Germany, plus international plants in US (Vineland NJ), India, Mexico, Czech Republic. Gerresheimer is vertically integrated — operates both primary glass tubing drawing capacity and downstream vial conversion at some sites. Listed company focused primarily on high-value pharmaceutical packaging; roughly 17-20% global pharmaceutical glass vial market share.

Japanese diversified medical device and pharmaceutical packaging company (TYO: 8086; ~¥500B revenue); headquartered in Osaka. Nipro is the largest pharmaceutical glass vial manufacturer in Japan and a major global supplier, holding an estimated 10-15% of global pharmaceutical glass vial market share. Nipro's pharma glass operations span borosilicate vial production (Nipro Pharma Corporation subsidiary) and medical device manufacturing. Nipro is one of the few manufacturers with both pharmaceutical glass tubing drawing capability AND vial conversion capacity in-house — a vertical integration comparable to SCHOTT Pharma. Major supplier to Japanese domestic pharmaceutical manufacturers; growing export market in Asia, India, and emerging markets. Also the world's largest manufacturer of hemodialysis equipment and supplies.

French pharmaceutical glass packaging company; subsidiary of Lam Industries (a French private equity-backed industrial group) following acquisition from Pochet Group (2017). SGD Pharma is a major European pharmaceutical glass vial and ampoule converter with primary operations in Sucy-en-Brie (France), Zell (Germany), and plants in Brazil and India. SGD Pharma focuses on Type I and Type II borosilicate glass containers including vials, ampoules, and bottles for parenteral drugs. After multiple ownership changes (formerly Saint-Gobain Desjonquères), SGD Pharma is one of Europe's top-3 independent pharmaceutical glass vial manufacturers and a significant supplier to European generics pharmaceutical companies.